Controlling Properties of Agglomerates for Chemical Processes

Iron ore pellets are hard spheres made from powdered ore and binders. Pellets are used to make iron, mainly in blast furnaces. Around the time that the pelletizing process was developed, starch was proposed as a binder because it’s viscous, adheres well to iron oxides, does not contaminate pellets and is relatively cheap. In practice, however, starch leads to weak pellets with rough surfaces – these increase the amount of dust generated within process equipment and during pellet shipping and handling. Thus, even though the usual binder (bentonite clay) contaminates pellets, pelletizers prefer it to starch or other organics. This dissertation describes three ways to make good starch-based binders for pellets. Importantly, they solve the usual problems of weak rough pellets and lots of dust. The three approaches are: (1) Addition of clay to starch. This is not a novel idea. In fact, it is the standard method used for their improvement. However, it has not been tested extensively with starch. This approach was expected to be – and indeed was – successful. (2) Addition of a clay-rich layer to green ball surfaces. This approach is a novel idea. The coating\u27s purpose was to mimic the good surface properties of standard bentonite-clay bonded pellets; as a benefit, clay consumption was significantly reduced. This approach was successful. (3) Addition of dispersants to starch. This approach is a novel idea. The intent of the dispersants was to enable pelletization to occur at lower moisture contents, thus leading to denser particle packing and lower porosity. The dispersants resulted in significantly stronger, smoother pellets without contaminating them with silica. Using approaches 1 and 3, starch can be used directly in traditional pelletizing operations, and importantly, in new pelletizing processes for new iron making operations. For approach 2, new application methods must be developed. Future engineering work is suggested as follows: design better dispersants for magnetic magnetite ores; incorporate the dispersing agent and starch into bead form for easy use; design a simple way to add coatings in existing drum-based pelletizing circuits; and optimize the coating composition to decrease both abrasion losses and pellet clustering (for new Direct Reduction pellets)

FACTORS INFLUENCING MATERIAL LOSS DURING IRON ORE PELLET HANDLING

Iron ore concentrate pellets have the potential to fracture and abrade during transportation and handling, which produces unwanted fine particulates and dust. Consequently, pellet producers characterize the abrasion resistance of their pellets, using an Abrasion Index (AI), to indicate whether their products will produce unacceptable levels of fines. However, no one has ever investigated whether the AI correlates to pellet dustiness. During the course of this research, we investigated the relationship between AI and iron ore concentrate pellet dustiness using a wide range of industrial and laboratory pellet samples. The results showed that, in general, AI can be used to indicate high levels of dust. However, for good-quality pellets, there was no correlation between the two. Thus, dust generation from shipping and handling pellets will depend on the quantity of pellets handled and how much they are handled. These results also showed that the type of industrial furnace used to harden iron ore concentrate pellets may affect their fines generation and potential dustiness

Bubble kinetics in a steady-state column of aqueous foam

We measure the liquid content, the bubble speeds, and the distribution of bubble sizes, in a vertical column of aqueous foam maintained in steady-state by continuous bubbling of gas into a surfactant solution. Nearly round bubbles accumulate at the solution/foam interface, and subsequently rise with constant speed. Upon moving up the column, they become larger due to gas diffusion and more polyhedral due to drainage. The size distribution is monodisperse near the bottom and polydisperse near the top, but there is an unexpected range of intermediate heights where it is bidisperse with small bubbles decorating the junctions between larger bubbles. We explain the evolution in both bidisperse and polydisperse regimes, using Laplace pressure differences and taking the liquid fraction profile as a given.Comment: 7 pages, 3 figure

Attention deficit hyperactivity and oppositional defiant disorder symptoms in adolescence and risk of substance use disorders - a general population-based birth cohort study

BACKGROUND: Externalizing symptoms are associated with risk of future substance use disorder (SUD). Few longitudinal studies exist using general population-based samples which assess the spectrum of attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms. AIMS/OBJECTIVES: We aimed to study the associations between adolescent ADHD symptoms and subsequent SUD and additionally examine whether the risk of SUD is influenced by comorbid oppositional defiant disorder (ODD) symptoms. METHODS: The Northern Finland Birth Cohort 1986 was linked to nationwide health care register data for incident SUD diagnoses until age 33 years (n = 6278, 49.5% male). ADHD/ODD-case status at age 16 years was defined using parent-rated ADHD indicated by Strengths and Weaknesses of ADHD symptoms and Normal Behaviors (SWAN) questionnaire with 95% percentile cut-off. To assess the impact of ODD comorbidity on SUD risk, participants were categorized into four groups based on their ADHD/ODD case status. Cox-regression analysis with hazard ratios (HRs) and 95% confidence intervals (CIs) were used to study associations between adolescent ADHD/ODD case statuses and subsequent SUD. RESULTS: In all, 552 participants (8.8%) presented with ADHD case status at the age of 16 years, and 154/6278 (2.5%) were diagnosed with SUD during the follow-up. ADHD case status was associated with SUD during the follow-up (HR = 3.84, 95% CI 2.69-5.50). After adjustments for sex, family structure, and parental psychiatric disorder and early substance use the association with ADHD case status and SUD remained statistically significant (HR = 2.60, 95% CI 1.70-3.98). The risk of SUD remained elevated in individuals with ADHD case status irrespective of ODD symptoms. CONCLUSIONS: ADHD in adolescence was associated with incident SUD in those with and without symptoms of ODD. The association of ADHD and SUD persisted even after adjustment for a wide range of potential confounds. This emphasizes the need to identify preventative strategies for adolescents with ADHD so as to improve health outcomes

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. In this double-blind, multicenter study, we randomly assigned patients to receive denosumab at a dose of 60 mg subcutaneously every 6 months or placebo (734 patients in each group). The primary end point was percent change in bone mineral density at the lumbar spine at 24 months. Key secondary end points included percent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 months, as well as incidence of new vertebral fractures. At 24 months, bone mineral density of the lumbar spine had increased by 5.6% in the denosumab group as compared with a loss of 1.0% in the placebo group (P<0.001); significant differences between the two groups were seen at as early as 1 month and sustained through 36 months. Denosumab therapy was also associated with significant increases in bone mineral density at the total hip, femoral neck, and distal third of the radius at all time points. Patients who received denosumab had a decreased incidence of new vertebral fractures at 36 months (1.5%, vs. 3.9% with placebo) (relative risk, 0.38; 95% confidence interval, 0.19 to 0.78; P=0.006). Rates of adverse events were similar between the two groups. Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. (ClinicalTrials.gov number, NCT00089674.

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A(mut)) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A(mut)-bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A(mut) arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance

Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Acute gastrointestinal (GI) bleeding is an important cause of mortality worldwide. Bleeding can occur from the upper or lower GI tract, with upper GI bleeding accounting for most cases. The main causes include peptic ulcer/erosive mucosal disease, oesophageal varices and malignancy. The case fatality rate is around 10% for upper GI bleeding and 3% for lower GI bleeding. Rebleeding affects 5-40% of patients and is associated with a four-fold increased risk of death. Tranexamic acid (TXA) decreases bleeding and the need for blood transfusion in surgery and reduces death due to bleeding in patients with trauma and postpartum haemorrhage. It reduces bleeding by inhibiting the breakdown of fibrin clots by plasmin. Due to the methodological weaknesses and small size of the existing trials, the effectiveness and safety of TXA in GI bleeding is uncertain. The Haemorrhage ALleviation with Tranexamic acid - Intestinal system (HALT-IT) trial aims to provide reliable evidence about the effects of TXA in acute upper and lower GI bleeding. METHODS: The HALT-IT trial is an international, randomised, double-blind, placebo-controlled trial of tranexamic acid in 12,000 adults (increased from 8000) with acute upper or lower GI bleeding. Eligible patients are randomly allocated to receive TXA (1-g loading dose followed by 3-g maintenance dose over 24 h) or matching placebo. The main analysis will compare those randomised to TXA with those randomised to placebo on an intention-to-treat basis, presenting the results as effect estimates (relative risks) and confidence intervals. The primary outcome is death due to bleeding within 5 days of randomisation and secondary outcomes are: rebleeding; all-cause and cause-specific mortality; thromboembolic events; complications; endoscopic, radiological and surgical interventions; blood transfusion requirements; disability (defined by a measure of patient's self-care capacity); and number of days spent in intensive care or high-dependency units. Subgroup analyses for the primary outcome will consider time to treatment, location of bleeding, cause of bleed and clinical Rockall score. DISCUSSION: We present the statistical analysis of the HALT-IT trial. This plan was published before the treatment allocation was unblinded. TRIAL REGISTRATION: Current Controlled Trials, ID: ISRCTN11225767. Registered on 3 July 2012; Clinicaltrials.gov, ID: NCT01658124. Registered on 26 July 2012

In Protection of Whose “Wellbeing?” Considerations of “Clauses and A/Effects” in Athlete Contracts

Contractual agreements have become an accepted part of participation processes for athletes in a variety of sport contexts. Closer readings of these contracts,however, pose several questions regarding organizational intentions and motivations,the conceptualization of athletes as "workers," and representation parity. In this article, we draw on four types of athlete contractual documents from both select international "amateur" and "professional" sport settings. Our key considerations include athletes' ownership over their image and identities; medical and health disclosures; lifestyle, behavioral and body choices, and restrictions beyond sport; adherence to organizational philosophy and commitments; and social media and publicity constraints. Our exegesis here encourages sport researchers to deliberate whose "wellbeing" matters most when signing that seductive dotted line